Evaluation of Cerebral Perfusion in Patients Undergoing Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis

Teruyuki Hirano

Abstract
Currently, the indication for thrombolytic therapy using intravenous recombinant tissue plasminogen activator (rt-PA) is restricted strictly to patients with acute ischemic stroke within 4.5 h of onset. The effect of rt-PA declines over time; therefore, we need to minimize the time delay while generating imaging information. The use of cerebral blood flow imaging is not recommended within this time window. Conversely, the balance of efficacy and the risk of bleeding complications differ among patients > 4.5 h after onset. Several ongoing studies are using mismatch concepts to extend the therapeutic time window for rt-PA. Long-awaited reliable software, such as RAPID and PMA, are now available to analyze computed tomography/magnetic resonance perfusion data. Patients with wake-up stroke (WUS) are another group that can be used to expand rt-PA candidates. Diffusion fluid-attenuated inversion recovery mismatch is a promising imaging surrogate to select good candidates with WUS. These trials will cause a therapeutic paradigm shift from time-based to tissue-based strategies in the near future.

Key words: recombinant tissue plasminogen activator, thrombolytic therapy, cerebral blood flow, mismatch, tissue-based strategy

Introduction
Thrombolytic therapy using intravenous recombinant tissue plasminogen activator (rt-PA) is a guideline-recommended grade A stroke therapy in many countries, including Japan, the United States, and Europe. The effect of this therapy depends on the time of its initiation from stroke onset. Conversely, a detailed evaluation of cerebral blood flow (CBF) and metabolism generates an understanding of each patient’s ischemic pathophysiology, as the brain requires a continuous supply of oxygen and glucose from CBF. Recent advanced neuroimaging techniques enable such information to be obtained within a few hours after stroke onset. However, the more information obtained from imaging, the more time is lost, and the chance of recovery becomes lesser. Thus, we need to consider on a case-by-case basis whether CBF imaging is useful for each patient.

1. Chance of salvage for ischemic tissue by reperfusion therapy
rt-PA thrombolytic therapy is derived from a clear and simple concept, i.e., obtain reperfusion by opening occluded vessels before brain damage becomes irreversible. The therapeutic time window differs among patients because advancement of the ischemic process depends on the level of hypoperfusion.

The possibility of tissue salvage by reperfusion was shown to depend on residual CBF in a study that enrolled 30 patients with acute ischemic stroke who underwent local fibrinolysis between 3 h and 6 h after onset. In the study, CBF was determined using single-photon emission computed tomography (SPECT) with 99mTc-HMPAO (99mTc-hexamethylpropyleneamineoxime). Ischemic tissue with CBF greater than 55% of cerebellar flow may still be salvageable, even with treatment initiated at 6 h after the onset of symptoms. Ischemic tissue with CBF less than 35% of cerebellar flow may be at risk for hemorrhage within the critical time window (Fig. 1). If we focus on the < 3 h area of the graph...
in Fig. 1, we see that there is a possibility of tissue salvage by timely reperfusion. On the contrary, the > 4.5 h area of the graph shows that the outcome of the ischemic tissue depends mainly on the level of residual CBF. One point we need to learn is that we must focus on shortening the treatment time to within a 4.5-h time window. At the later time window, i.e., > 4.5 h after onset, treatment decision should be made on the evaluation of CBF and tissue viability.

2. CBF imaging within the 4.5-h time window

CBF imaging is not needed in this time window. The 2nd Japanese guidelines for the intravenous application of rt-PA state clearly that diagnostic imaging should be limited to the minimum necessary to avoid unnecessary loss of time. The presence of early ischemic changes (EICs) should be identified quickly and accurately using non-contrast computed tomography (CT) or diffusion-weighted magnetic resonance imaging (MRI). Residual CBF should be estimated from limited information such as elapsed time from onset, clinical manifestation, size and location of EICs, and the presence of occluded vessels (if available).

The presence of an EIC on CT depends on residual CBF and the time from onset. These are related significantly and independently according to our study evaluating 53 patients with supratentorial acute ischemic stroke in whom \(^{99m}\text{Tc-HMPAO SPECT}\) was performed within 6 h of onset. Furthermore, the lower the Alberta Stroke Program Early CT Score (ASPECTS), a semi-quantitative standardized method for EIC evaluation, the more severe the degree of hypoperfusion (Fig. 2). It is estimated that patients with large EICs have an ischemic core with very low CBF, resulting in a high rate of symptomatic intracranial hemorrhage (sICH). In fact, the odds for sICH risk were calculated as 2.2 for every 1 point decrease on ASPECTS among 103 patients enrolled in the Japan Alteplase Clinical Trial.

A recent topic of EICs is the presence of isolated cortical swelling (iCS) without concomitant parenchymal hypodensity (Fig. 3), which is a subtype of EIC that differs from tissues exhibiting parenchymal hypodensity. Generally, brain tissue exhibiting EICs is thought to be damaged irreversibly, but tissue with ICS preserving gray-white matter differentiation might have a chance of recovery with timely reperfusion. One possible explanation for ICS pathophysiology relates to the enlarged cerebral blood volume that compensates for reduced perfusion pressure. Another explanation is the timing of CT evaluation, which is performed too early to show any change in CT value, ICS should be excluded from the ASPECTS evaluation because it is believed to contain ischemic penumbra, although this concept is yet to be confirmed.
3. Decision making for rt-PA thrombolysis beyond 4.5 h after onset

Whether or not the patient should be treated with revascularization depends on how much salvageable tissue still exists. In this situation, neuroimaging plays a critical role in making a treatment decision. A mismatch between irreversibly damaged tissue, such as diffusion high-signal lesions and tissue with decreased CBF, shown on CT perfusion or MR perfusion images, which could be salvaged by reperfusion therapy, is used increasingly in clinical studies. Among these, diffusion-perfusion mismatches (DPMs) on multimodality MRI are attracting attention.

Both the Echo-Planar imaging THrombolytic Evaluation Trial (EPiTHET) and Diffusion and perfusion imaging Evaluation For Understanding Stroke Evolution (DEFUSE) enrolled patients with acute stroke between 3 h and 6 h of onset. These trials showed patients with a small core and DPM are good candidates for thrombolytic therapy. The definition of DPM employed in these trials was: (1) diffusion-weighted imaging (DWI) lesion volume < 70 mL, (2) DPM lesion volume > 10 mL, and (3) perfusion-weighted imaging (PWI):DWI ratio > 1.2. Such criteria have extreme clinical importance to patient selection; however, this has yet to be validated formally.

In addition, the classical penumbral concept with the preservation of an annular pattern of mismatch surrounding the infarct core, has been shown to present within the early hours after stroke onset. After that point, a dissociation between DWI and PWI lesions occurs over time (Fig. 4). In other words, the classical mismatch pattern fragments in a time-dependent manner, because of partial reperfusion of DWI positive tissues. Therefore, a simple subtraction of DWI volume from PWI lesion volume will underestimate the true penumbral volume (Fig. 5). Using a three-dimensional (3D) co-registration method, in fact, re-analysis of the data from EPiTHET showed a significant reduction in infarct volume expansion when rt-PA was administered to patients with 3D-proven DPM.

An international collaborative consortium on acute stroke imaging including Japanese and American researchers is currently working on evaluating and improving the accuracy and/or reproducibility of the CT/MR perfusion imaging technique. As a result, reliable and accurate automated analysis software, such as RAPID developed at Stanford University or PMA by ASIST-Japan, is now available for clinical use. Two identically designed randomized controlled trials, EXTending the time for Thrombolysis in Emergency Neurological Deficit (EXTEND) and European Cooperative Acute Stroke Study 4, are
Fig. 4 Example of non-classical pattern of mismatch. Representative case showing fragmentation of the co-registered mismatch lesion. A: Diffusion weighted-image (DWI). B: DWI abnormal lesion (red) and hypoperfusion lesion (green) superimposed on DWI. Note fragmentation of the pattern. C: DWI abnormal lesion and hypoperfusion lesion with brain image (DWI) removed. Adopted from reference 18 with permission.

Fig. 5 Topographic relationship between the ischemic penumbra and core. Diagram of the position between high-signal lesions on diffusion-weighted magnetic resonance imaging (MRI) and abnormalities on perfusion-weighted (PWI) MRI. As the time from onset increases (A, B, C), the diffusion-weighted imaging (DWI)-abnormal area (equivalent to the ischemic core) expands and the PWI-abnormal area shrinks. As shown in example C, an ischemic core may be present outside of the PWI-abnormal area (o-DWI). In this case, penumbral volume is the PWI-abnormal zone subtracted by the core (w-DWI). As shown in example C, an ischemic core may be present outside of the PWI-abnormal area (o-DWI). In this case, penumbral volume is the PWI-abnormal zone subtracted by the core (w-DWI). A simple subtraction (PWI − [w-DWI + o-DWI]) leads to an underestimation of the true penumbral volume.

4. Expanding the indication for unknown onset stroke: establishing a tissue-based strategy

Patients who notice their symptoms upon waking, i.e., wake-up stroke (WUS), are also to be enrolled in the EXTEND trial. Although approximately 25% of acute stroke patients suffer from stroke symptoms with an unclear onset time or onset during sleep,21–23) such patients are usually excluded from rt-PA thrombolysis as the time of onset is defined by the guidelines to be the last known well time. However, these patients reportedly have similar early ischemic findings on initial CT or MRI as those presenting with a clear onset time within 3 or 6 h of symptom recognition.24) In addition, all subtypes of stroke have an early morning peak, indicating that patients with WUS might be within the time window for rt-PA thrombolysis. In the trial, DPM will be used to identify patients likely to benefit from treatment. The paradigm shift from a time-based strategy to a tissue-based strategy is the most exciting topic of recent acute stroke research.

Another approach to identify candidates for rt-PA thrombolysis, is the utilization of a DWI-fluid-attenuated inversion recovery (FLAIR) mismatch (Fig. 6). This concept depends on the hypothesis that signal changes on FLAIR remain invisible until 4.5 h from onset.25) Previous reports, including one from Japan,26) showed rt-PA thrombolysis was effective in such FLAIR-negative patients if the ischemic core, i.e., high DWI signal, remains small enough. Several multicenter prospective studies are currently ongoing internationally, such as efficacy and safety of MRI-based thrombolysis in WUS in the European Union27) and THrombolysis for Acute Wake-up and unclear-onset Strokes in Japan.28)
CBF Imaging and rt-PA Thrombolysis

5. Novel thrombolytic agents and CBF imaging
Currently, alteplase is the only thrombolytic agent available for clinical use. However, several problems, such as a short half-life, neurotoxicity, and low fibrin specificity, have been reported. Two possible alternatives that improved these problems are currently under development utilizing CBF imaging.

Desmoteplase, with the same structure as the plasminogen activator present in the saliva of vampire bats, has a longer half-life than alteplase and exhibits no neurotoxicity. The phase II clinical trials Desmoteplase In Acute Ischemic Stroke (DIAS) and Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS) have generated promising results; however, a phase III trial (DIAS-2) failed to show efficacy or dose-dependency. Several problems have been discussed. One significant factor is that imaging diagnosis was not standardized across facilities. In fact, integrated analysis of DIAS/DEDAS/DIAS-2 showed a therapeutic effect in a particular group of patients whose absolute difference in DPM was > 60 mL.

Tenecteplase is another novel thrombolytic agent modified from alteplase using genetic engineering techniques. It shows high fibrin specificity and strong resistance to plasminogen activator inhibitor-1. The Tenecteplase versus Alteplase for Acute Ischemic Stroke study enrolled 75 patients with acute ischemic stroke within 6 h of onset, who were selected on the basis of arterial occlusion and CT perfusion. Compared to the alteplase group, patients in the tenecteplase group showed improved reperfusion rates and neurological improvement in a dose-dependent manner. In this study, the ischemic core was defined as < 45% of the contralateral CBF. In addition, the penumbral area was defined as a prolonged mean transit time > 125% of the contralateral side. Using these criteria, a phase III trial, Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation, is currently ongoing targeting patients with stroke within 4.5 h of onset.

Conclusion

Toward the expanded indication for rt-PA thrombolysis, penumbra evaluation using CBF imaging is in the limelight. However, even in the era of a tissue-based strategy, time should never be wasted relying on imaging findings.

Conflicts of Interest Disclosure

The author declares no conflict of interest regarding this review article.

References

1) Shinohara Y, Yanagihara T, Abe K, Yoshimine T, Fujinaka T, Chuma T, Ochi F, Nagayama M, Ogawa A, Suzuki N, Katayama Y, Kimura A, Minematsu K: II. Cerebral infarction/transient ischemic attack (TIA). J Stroke Cerebrovasc Dis 20: S31–S73, 2011
2) Jauch EC, Saver JL, Adams HP, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology: Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44: 870–947, 2013
3) European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee: Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 25: 457–507, 2008
4) Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, Brott T, Cohen G, Davis S, Donnan G, Grotta J, Howard G, Kaste M, Koga M, von Kummer R, Lansberg M, Lindley RI, Murray G, Olivot JM, Parsons M, Tilley B, Toni D, Toyoda K, Wahlgren N, Wardlaw J, Whiteley W, del Zoppo GJ, Baigent C, Sanderson P, Hacke W; Stroke Thrombolysis Trialists’ Collaborative Group: Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic

Neurol Med Chir (Tokyo) 55, October, 2015
stroke: a meta-analysis of individual patient data from randomised trials. *Lancet* 384: 1929–1935, 2014
5) Mori E: Safety and efficacy of fibrinolytic agents in acute ischemic stroke. *Cerebrovasc Dis* 3: 264–268, 1993
6) Minematsu K, Yamaguchi T, Omae T: ‘Spectacular shrinking deficit’: rapid recovery from a major hemispheric syndrome by migration of an embolus. *Neurology* 42: 157–162, 1992
7) Jones TH, Morawetz RB, Crowell RM, Marcoux FW, FitzGibbon SJ, DeGirolami U, Ojemann RG: Thresholds of focal cerebral ischemia in awake monkeys. *J Neurosurg* 54: 773–782, 1981
8) Ueda T, Sakaki S, Yuh WT; Nochide I, Ohta S: Outcome in acute stroke with successful intra-arterial thrombolysis and predictive value of initial single-photon emission-computed tomography. *J Cereb Blood Flow Metab* 19: 99–108, 1999
9) Minematsu K, Toyoda K, Hirano T, Kimura K, Kondo R, Mori E, Nakagawara J, Sakai N, Shikawa Y, Tanahashi N, Yasaki M, Katayama Y, Miyamoto S, Ogawa A, Sasaki M, Suga S, Yamaguchi T; Japan Stroke Society: Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society. *J Stroke Cerebrovasc Dis* 22: 571–600, 2013
10) Hirano T, Yonehara T, Inatomi Y, Hashimoto Y, Uchino M: Presence of early ischemic changes on computed tomography depends on severity and the duration of hypoperfusion: a single photon emission-computed tomographic study. *Stroke* 36: 2601–2608, 2005
11) Hirano T, Sasaki M, Tomura N, Ito Y, Kobayashi S; Japan Alteplase Clinical Trial Group: Low Alberta stroke program early computed tomography score within 3 hours of onset predicts subsequent symptomatic intracranial hemorrhage in patients treated with 0.6 mg/kg Alteplase. *J Stroke Cerebrovasc Dis* 21: 898–902, 2012
12) Na DG, Kim EY, Ryoo JW, Lee KH, Roh HG, Kim SS, Song IC, Chang KH: CT sign of brain swelling without concomitant parenchymal hypodensity: comparison with diffusion- and perfusion-weighted MR imaging. *Radiology* 235: 992–948, 2005
13) Butcher KS, Lee SB, Parsons MW, Allport L, Fink J, Tress B, Donnan G, Davis SM; EPITHET Investigators: Differential prognosis of isolated cortical swelling and hypodensity on CT in acute stroke. *Stroke* 38: 941–947, 2007
14) Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, Barber PA, Bladin C, De Silva DA, Byrnes G, Chalk JB, Fink JN, Kimber TE, Schultz D, Hand PJ, Frayne J, Hankey G, Muir K, Gerraty R, Tress BM, Desmond PM; EPITHET investigators: Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. *Lancet Neurol* 7: 299–309, 2008
15) Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, Bammer R, Kakuda W, Lansberg MG, Shuaib A, Coplin W, Hamilton S, Moseley M, Marks MP; DEFUSE Investigators: Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. *Ann Neurol* 60: 508–517, 2006
16) Sasaki M, Kudo K, Christensen S, Yamashita F, Goodwin J, Higuchi S, Ogawa A; Penumbra imaging by using perfusion computed tomography and perfusion-weighted magnetic resonance imaging: current concepts. *J Stroke Cerebrovasc Dis* 22: 1212–1215, 2013
17) Ma H, Zavala JA, Teoh H, Churilov L, Gunawan M, Ly J, Wright P, Phan T, Arakawa S, Davis SM, Donnan GA; Fragmentation of the classical magnetic resonance mismatch “penumbral” pattern with time. *Stroke* 40: 3752–3757, 2009
18) Ogata T, Nagakane Y, Christensen S, Ma H, Campbell BC, Churilov L, Olivot JM, Desmond PM, Albers GW, Davis SM, Donnan GA; EPITHET and DEFUSE Investigators: A topographic study of the evolution of the MR DWI/PWI mismatch pattern and its clinical impact: a study by the EPITHET and DEFUSE Investigators. *Stroke* 42: 1596–1601, 2011
19) Nagakane Y, Christensen S, Brekenfeld C, Ma H, Churilov L, Parsons MW, Levi CR, Butcher KS, Peeters A, Barber PA, Bladin CF, De Silva DA, Fink J, Kimber TE, Schultz DW, Muir KW, Tress BM, Desmond PM, Davis SM, Donnan GA; EPITHET Investigators: EPITHET: Positive Result After Reanalysis Using Baseline Diffusion-Weighted Imaging/Perfusion-Weighted Imaging Co-Registration. *Stroke* 42: 59–64, 2011
20) Ma H, Parsons MW, Christensen S, Campbell BC, Churilov L, Connelly A, Yan B, Bladin C, Phan T, Barber AF; Read S, Hankey GJ, Markus R, Wijeratne T, Grimley R, Mahant N, Kleining T, Sturm J, Lee A, Blacker D, Gerraty R, Krause M, Desmond PM, McBride SJ, Carey L, Howells DW, Hsu CY, Davis SM, Donnan GA; EXTEND investigators: A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXTending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND). *Int J Stroke* 7: 74–80, 2012
21) Mackey J, Kleindorfer D, Sucharew H, Moomaw CJ, Kissela BM, Alwell K, Flaherty ML, Woo D, Khatri P, Adeoye O, Ferioli S, Khoury JC, Hornung R, Broderick JP: Population-based study of wake-up strokes. *Neurology* 76: 1662–1667, 2011
22) Kang DW, Kwon JY, Kwon SU, Kim JS: Wake-up or unclear-onset strokes: are they waking up to the world of thrombolysis therapy? *Int J Stroke* 7: 311–320, 2012
23) Koton S, Tanne D, Bornstein NM; NASIS Investigators: Ischemic stroke on awakening: patients’ characteristics, outcomes and potential for reperfusion therapy. *Neuroepidemiology* 39: 149–153, 2012
24) Todo K, Moriwaki H, Saito K, Tanaka M, Oe H, Naritomi H: Early CT findings in unknown-onset and wake-up strokes. *Cerebrovasc Dis* 21: 367–371, 2006

25) Emeriau S, Serre I, Toufours O, Pombourcq F, Oppenheim C, Pierot L: Can diffusion-weighted imaging-fluid-attenuated inversion recovery mismatch (positive diffusion-weighted imaging/negative fluid-attenuated inversion recovery) at 3 Tesla identify patients with stroke at <4.5 hours? *Stroke* 44: 1647–1651, 2013

26) Aoki J, Kimura K, Shibazaki K, Sakamoto Y: Negative fluid-attenuated inversion recovery-based intravenous thrombolysis using recombinant tissue plasminogen activator in acute stroke patients with unknown onset time. *Cerebrovasc Dis Extra* 3: 35–45, 2013

27) Thomalla G, Fiebach JB, Østergaard L, Pedraza S, Thijs V, Nighoghossian N, Roy P, Muir KW, Ebinger M, Cheng B, Galinovic I, Cho TH, Puig J, Boutitie F, Simonsen CZ, Endres M, Fiehler J, Gerloff C; WAKE-UP investigators: A multicenter, randomized, double-blind, placebo-controlled trial to test efficacy and safety of magnetic resonance imaging-based thrombolysis in wake-up stroke (WAKE-UP). *Int J Stroke* 9: 829–836, 2014

28) Koga M, Toyoda K, Kimura Y, Yamamoto H, Sasaki M, Hamasaki T, Kitazono T, Aoki J, Seki K, Homma K, Sato S, Minematsu K; THAWS investigators: Thrombolysis for Acute Wake-up and unclear-onset Strokes with alteplase at 0.6 mg/kg (THAWS) Trial. *Int J Stroke* 9: 1117–1124, 2014

29) Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S; DIAS Study Group: The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. *Stroke* 36: 66–73, 2005

30) Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, Sachara C, Soehngen M, Warach S, Hacke W; DEDAS Investigators: Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. *Stroke* 37: 1227–1231, 2006

31) Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, Kaste M, Lipka LJ, Pedraza S, Ringleb PA, Rowley HA, Schneider D, Schwamm LH, Leal JS, Soehngen M, Teal PA, Wilhelm-Ogunbiyi K, Wintermark M, Warach S: Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. *Lancet Neurol* 8: 141–150, 2009

32) Warach S, Al-Rawi Y, Furlan AJ, Fiebach JB, Wintermark M, Lindstén A, Smyej J, Bharucha DB, Pedraza S, Rowley HA: Refinement of the magnetic resonance diffusion-perfusion mismatch concept for thrombolytic patient selection: insights from the desmoteplase in acute stroke trials. *Stroke* 43: 2313–2318, 2012

33) Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, O’Brien B, Bladin C, McElduff P, Allen C, Bateman G, Donnan G, Davis S, Levi C: A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. *N Engl J Med* 366: 1099–1107, 2012

Address reprint requests to: Teruyuki Hirano, MD, PhD, Department of Stroke and Cerebrovascular Medicine, Kyorin University, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan.
e-mail: terry@ks.kyorin-u.ac.jp